{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:58:21Z","timestamp":1762376301284},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1097\/md.0000000000008039","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T16:39:49Z","timestamp":1508344789000},"page":"e8039","source":"Crossref","is-referenced-by-count":8,"title":["Significance of monitoring plasma concentration of voriconazole in a patient with liver failure"],"prefix":"10.1097","volume":"96","author":[{"given":"Xiaoyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-29-20210226","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s12072-016-9753-2","article-title":"Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management","volume":"10","author":"Philips","year":"2016","journal-title":"Hepatol Int"},{"key":"R2-29-20210226","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/myc.12044","article-title":"Invasive fungal infections secondary to acute-on-chronic liver failure: a retrospective study","volume":"56","author":"Lin","year":"2013","journal-title":"Mycoses"},{"key":"R3-29-20210226","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R4-29-20210226","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicro Agents Chemother"},{"key":"R5-29-20210226","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1128\/AAC.49.8.3569-3571.2005","article-title":"Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum","volume":"49","author":"Khoschsorur","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-29-20210226","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.clinbiochem.2007.07.024","article-title":"Measurement of voriconazole in serum and plasma","volume":"40","author":"Langman","year":"2007","journal-title":"Clinic Biochem"},{"key":"R7-29-20210226","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole","volume":"30","author":"Br\u00fcggemann","year":"2008","journal-title":"Therap Drug Monit"},{"key":"R8-29-20210226","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12281-011-0050-1","article-title":"Update on antifungal drug dosing and therapeutic drug monitoring","volume":"5","author":"Trifilio","year":"2011","journal-title":"Curr Fungal Infect Rep"},{"key":"R9-29-20210226","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: a new triazole antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann Pharmacother"},{"key":"R10-29-20210226","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/ehm.09.13","article-title":"Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections","volume":"2","author":"Cecil","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"R11-29-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00520-009-0783-3","article-title":"Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"19","author":"Mattiuzzi","year":"2011","journal-title":"Support Care Cancer"},{"key":"R12-29-20210226","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.09.011","article-title":"Voriconazole hepatotoxicity in severe liver dysfunction","volume":"66","author":"Solis-Munoz","year":"2013","journal-title":"J Infection"},{"key":"R13-29-20210226","first-page":"274","article-title":"Severe phototoxicity associated with long-term voriconazole treatment","volume":"9","author":"V\u00f6hringer","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"R14-29-20210226","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1248\/yakushi.128.1811","article-title":"Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection","volume":"128","author":"Okuda","year":"2008","journal-title":"Yakugaku Zasshi"},{"key":"R15-29-20210226","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-29-20210226","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R17-29-20210226","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740330903485637","article-title":"Voriconazole therapeutic drug monitoring: focus on safety","volume":"9","author":"Pasqualotto","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"R18-29-20210226","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/INF.0b013e3182566311","article-title":"Voriconazole-induced phototoxicity in children","volume":"31","author":"Bernhard","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R19-29-20210226","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"R20-29-20210226","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R21-29-20210226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5414\/CP202014","article-title":"Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections","volume":"52","author":"Kim","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R22-29-20210226","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0091270008327537","article-title":"CYP2C19 genotype is a major factor contributing to the highly variabl pharmacokinetics of voriconazole","volume":"49","author":"Weiss","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R23-29-20210226","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"R24-29-20210226","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","article-title":"Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype","volume":"68","author":"Scholz","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R25-29-20210226","first-page":"S357","article-title":"Comparison of plasma trough concentrations of voriconazole in patients with or without co-medication of ranitidine or pantoprazole","volume":"13","author":"Heinz","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"R26-29-20210226","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.03820-14","article-title":"Inflammation is associated with voriconazole trough concentrations","volume":"58","author":"van Wanrooy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-29-20210226","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1155\/2014\/214813","article-title":"Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy","volume":"25","author":"Saini","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"R28-29-20210226","first-page":"1805e8","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"R29-29-20210226","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/AAC.01316-08","article-title":"Serial plasma voriconazoleconcentrations after allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Trifilio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-29-20210226","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/374248","article-title":"Safety of voriconazole and dose individualization","volume":"36","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:33:02Z","timestamp":1620959582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201710200-00029"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":30,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008039","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}